New guidelines released in February 2026 by the American Heart Association and the American College of Cardiology outline a detailed approach to diagnosing and treating acute pulmonary embolism in adults.
How the 2026 guideline classifies severity
Patients are placed into five categories, A through E, based on symptom burden and risk scores such as the pulmonary embolism severity index (PESI) and the simplified PESI. Category A covers incidental, asymptomatic clots, while category E represents full cardiopulmonary failure with persistent shock.
Categories B and C split further by clot location and right‑ventricular strain, using biomarkers like troponin and brain‑type natriuretic peptide. Category D denotes incipient failure, divided into transient hypotension (D1) and normotensive shock (D2). The framework helps clinicians match therapy intensity to patient risk.
Anticoagulant choices highlighted in the guideline
Anticoagulation remains the foundation of treatment for all but the most severe cases. Direct oral anticoagulants (DOACs) – apixaban, dabigatran, edoxaban and rivaroxaban – are preferred over vitamin K antagonists for most patients, especially those in categories A and B who can be managed as outpatients.
Related: User access denied after system block
These agents inhibit factor Xa or thrombin, preventing clot propagation. Their use is supported in patients with mild‑to‑moderate chronic kidney disease (CKD stages 2‑3) to lower major bleeding rates. In severe CKD (stage 4‑5) the recommendation is less clear, and clinicians must weigh bleeding risk against efficacy.
Liver impairment also influences drug selection. For patients with Child‑Pugh class A or B disease, they may be reasonable, but they are discouraged in class C because of heightened bleeding potential.
Thrombolytic therapy is reserved for categories D and E, where hemodynamic compromise threatens survival. Systemic thrombolysis with agents such as alteplase or tenecteplase can reduce mortality but carries a higher risk of major bleeding.
Catheter‑directed thrombolysis (CDT) delivers lower drug doses directly to the clot and has been associated with reduced right‑ventricular strain and fewer bleeding events in intermediate‑risk patients. A meta‑analysis comparing CDT with systemic thrombolysis found lower odds of death (OR 0.4) and intracerebral hemorrhage (OR 0.44) for the catheter approach, though most contributing studies were small.
Related: Cosmetic jars: no shortage of choice
Patients who are pregnant or nursing may receive either LMWH or unfractionated heparin, as both are considered safe in these populations.
Pharmacists are expected to oversee medication selection, dosing adjustments for renal or hepatic impairment, and monitoring of anti‑Xa levels when indicated. Their expertise helps ensure that anticoagulant therapy aligns with the detailed recommendations of the 2026 guideline.
Understanding the stratification system and the relative benefits of DOACs versus traditional agents is essential for clinicians managing acute pulmonary embolism. The guidelines aim to balance efficacy with safety, especially in patients with comorbid conditions that complicate therapy.